[1]
|
Okamura, K., Kabasawa, T., Saito, T., et al. (2024) Resident Memory T Cell Contributes to the Phenotype of Inflammatory Vitiligo. Journal of Dermatological Science, 113, 74-76. https://doi.org/10.1016/j.jdermsci.2024.01.002
|
[2]
|
Shah, F., Giri, P.S., Bharti, A.H., et al. (2024) Compromised Melanocyte Survival Due to Decreased Suppression of CD4 & CD8 Resident Memory T Cells by Impaired TRM-Regulatory T Cells in Generalized Vitiligo Patients. Experimental Dermatology, 33, E14982. https://doi.org/10.1111/exd.14982
|
[3]
|
Shah, F., Patel, S., Begum, R., et al. (2021) Emerging Role of Tissue Resident Memory T Cells in Vitiligo: From Pathogenesis to Therapeutics. Autoimmunity Reviews, 20, Article ID: 102868. https://doi.org/10.1016/j.autrev.2021.102868
|
[4]
|
Frisoli, M.L., Essien, K. and Harris, J.E. (2020) Vitiligo: Mechanisms of Pathogenesis and Treatment. Annual Review of Immunology, 38, 621-648. https://doi.org/10.1146/annurev-immunol-100919-023531
|
[5]
|
Chen, J., Li, S. and Li, C. (2021) Mechanisms of Melanocyte Death in Vitiligo. Medicinal Research Reviews, 41, 1138-1166. https://doi.org/10.1002/med.21754
|
[6]
|
Wang, Y., Li, S. and Li, C. (2019) Perspectives of New Advances in the Pathogenesis of Vitiligo: From Oxidative Stress to Autoimmunity. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 25, 1017-1023. https://doi.org/10.12659/MSM.914898
|
[7]
|
Van Den Boorn, J.G., Konijnenberg, D., Dellemijn, T.A.M., et al. (2009) Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients. The Journal of Investigative Dermatology, 129, 2220-2232. https://doi.org/10.1038/jid.2009.32
|
[8]
|
Yang, L., Wei, Y., Sun, Y., et al. (2015) Interferon-Gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: A Pivotal Role of CD8 Cytotoxic T Lymphocytes in Vitiligo. Acta Dermato-Venereologica, 95, 664-670. https://doi.org/10.2340/00015555-2080
|
[9]
|
Grimes, P.E., Morris, R., Avaniss-Aghajani, E., et al. (2004) Topical Tacrolimus Therapy for Vitiligo: Therapeutic Responses and Skin Messenger RNA Expression of Proinflammatory Cytokines. Journal of the American Academy of Dermatology, 51, 52-61. https://doi.org/10.1016/j.jaad.2003.12.031
|
[10]
|
Rashighi, M., Agarwal, P., Richmond, J.M., et al. (2014) CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo. Science Translational Medicine, 6, 223-223. https://doi.org/10.1126/scitranslmed.3007811
|
[11]
|
Boukhedouni, N., Martins, C., Darrigade, A.S., et al. (2020) Type-1 Cytokines Regulate MMP-9 Production and E-Cadherin Disruption to Promote Melanocyte Loss in Vitiligo. JCI Insight, 5, E133772. https://doi.org/10.1172/jci.insight.133772
|
[12]
|
Lee, E.J., Kim, J.Y., Yeo, J.H., et al. (2024) ISG15-USP18 Dysregulation by Oxidative Stress Promotes IFN-γ Secretion from CD8 T Cells in Vitiligo. The Journal of Investigative Dermatology, 144, 273-283.E11. https://doi.org/10.1016/j.jid.2023.08.006
|
[13]
|
Liu, H., et al. (2023) The IFN-γ-CXCL9/CXCL10-CXCR3 Axis in Vitiligo: Pathological Mechanism and Treatment. European Journal of Immunology, 54, e2250281. https://pubmed.ncbi.nlm.nih.gov/37937817/
|
[14]
|
Xie, B., Zhu, Y., Shen, Y., et al. (2023) Treatment Update for Vitiligo Based on Autoimmune Inhibition and Melanocyte Protection. Expert Opinion on Therapeutic Targets, 27, 189-206. https://doi.org/10.1080/14728222.2023.2193329
|
[15]
|
Hamzavi, I., Rosmarin, D., Harris, J.E., et al. (2022) Efficacy of Ruxolitinib Cream in Vitiligo by Patient Characteristics and Affected Body Areas: Descriptive Subgroup Analyses from a Phase 2, Randomized, Double-Blind Trial. Journal of the American Academy of Dermatology, 86, 1398-1401. https://doi.org/10.1016/j.jaad.2021.05.047
|
[16]
|
Craiglow, B.G. and King, B.A. (2015) Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatology, 151, 1110-1112. https://doi.org/10.1001/jamadermatol.2015.1520
|
[17]
|
Song, H., Hu, Z., Zhang, S., et al. (2022) Effectiveness and Safety of Tofacitinib Combined with Narrowband Ultraviolet B Phototherapy for Patients with Refractory Vitiligo in Real-World Clinical Practice. Dermatologic Therapy, 35, E15821. https://doi.org/10.1111/dth.15821
|
[18]
|
Guttman-Yassky, E., Del Duca, E., Da Rosa, J.C., et al. (2024) Improvements in Immune/Melanocyte Biomarkers with JAK3/TEC Family Kinase Inhibitor Ritlecitinib in Vitiligo. The Journal of Allergy and Clinical Immunology, 153, 161-172.E8. https://doi.org/10.1016/j.jaci.2023.09.021
|
[19]
|
Agarwal, P., Rashighi, M., Essien, K.I., et al. (2015) Simvastatin Prevents and Reverses Depigmentation in a Mouse Model of Vitiligo. The Journal of Investigative Dermatology, 135, 1080-1088. https://doi.org/10.1038/jid.2014.529
|
[20]
|
Wu, H., Liao, W., Li, Q., et al. (2018) Pathogenic Role of Tissue-Resident Memory T Cells in Autoimmune Diseases. Autoimmunity Reviews, 17, 906-911. https://doi.org/10.1016/j.autrev.2018.03.014
|
[21]
|
Richmond, J.M., Strassner, J.P., Rashighi, M., et al. (2019) Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo. Journal of Investigative Dermatology, 139, 769-778. https://doi.org/10.1016/j.jid.2018.10.032
|
[22]
|
Boniface, K., Jacquemin, C., Darrigade, A.S., et al. (2018) Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3. Journal of Investigative Dermatology, 138, 355-364. https://doi.org/10.1016/j.jid.2017.08.038
|
[23]
|
Pan, Y., Tian, T., Park, C.O., et al. (2017) Survival of Tissue-Resident Memory T Cells Requires Exogenous Lipid Uptake and Metabolism. Nature, 543, 252-256. https://doi.org/10.1038/nature21379
|
[24]
|
Lin, R., Zhang, H., Yuan, Y., et al. (2020) Fatty Acid Oxidation Controls CD8 Tissue-Resident Memory T-Cell Survival in Gastric Adenocarcinoma. Cancer Immunology Research, 8, 479-492. https://doi.org/10.1158/2326-6066.CIR-19-0702
|
[25]
|
Pan, Y. and Kupper, T.S. (2018) Metabolic Reprogramming and Longevity of Tissue-Resident Memory T Cells. Frontiers in Immunology, 9, Article No. 1347. https://doi.org/10.3389/fimmu.2018.01347
|
[26]
|
Dikiy, S. and Rudensky, A.Y. (2023) Principles of Regulatory T Cell Function. Immunity, 56, 240-255. https://doi.org/10.1016/j.immuni.2023.01.004
|
[27]
|
Zhang, Q., Cui, T., Chang, Y., et al. (2018) HO-1 Regulates the Function of Treg: Association with the Immune Intolerance in Vitiligo. Journal of Cellular and Molecular Medicine, 22, 4335-4343. https://doi.org/10.1111/jcmm.13723
|
[28]
|
Giri, P.S., Patel, S.S. and Dwivedi, M. (2023) Altered Regulatory T Cell-Mediated Natural Killer Cells Suppression May Lead to Generalized Vitiligo. Human Immunology, 85, Article ID: 110737. https://doi.org/10.1016/j.humimm.2023.110737
|
[29]
|
Zhang, X., Liu, D., He, M., et al. (2021) Polymeric Nanoparticles Containing Rapamycin and Autoantigen Induce Antigen-Specific Immunological Tolerance for Preventing Vitiligo in Mice. Human Vaccines & Immunotherapeutics, 17, 1923-1929. https://doi.org/10.1080/21645515.2021.1872342
|
[30]
|
Chen, J., Wang, X., Cui, T., et al. (2022) Th1-Like Treg in Vitiligo: An Incompetent Regulator in Immune Tolerance. Journal of Autoimmunity, 131, Article ID: 102859. https://doi.org/10.1016/j.jaut.2022.102859
|
[31]
|
Eby, J.M., Kang, H.K., Tully, S.T., et al. (2015) CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo. The Journal of Investigative Dermatology, 135, 1574-1580. https://doi.org/10.1038/jid.2015.26
|
[32]
|
Li, H., Wang, C., Li, X., et al. (2021) CCL17-CCR4 Axis Contributes to the Onset of Vitiligo in Mice. Immunity, Inflammation and Disease, 9, 702-709. https://doi.org/10.1002/iid3.423
|
[33]
|
Essien, K.I., Katz, E.L., Strassner, J.P., et al. (2022) Regulatory T Cells Require CCR6 for Skin Migration and Local Suppression of Vitiligo. Journal of Investigative Dermatology, 142, 3158-3166.E7. https://doi.org/10.1016/j.jid.2022.05.1090
|
[34]
|
Arjomandnejad, M., Kopec, A.L. and Keeler, A.M. (2022) CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications. Biomedicines, 10, Article No. 287. https://doi.org/10.3390/biomedicines10020287
|
[35]
|
Sun, Y., Yuan, Y., Zhang, B., et al. (2023) CARs: A New Approach for the Treatment of Autoimmune Diseases. Science China Life Sciences, 66, 711-728. https://doi.org/10.1007/s11427-022-2212-5
|
[36]
|
Mukhatayev, Z., Dellacecca, E.R., Cosgrove, C., et al. (2020) Antigen Specificity Enhances Disease Control by Tregs in Vitiligo. Frontiers in Immunology, 11, Article ID: 581433. https://www.frontiersin.org/articles/10.3389/fimmu.2020.581433 https://doi.org/10.3389/fimmu.2020.581433
|
[37]
|
Sushama, S., Dixit, N., Gautam, R.K., et al. (2019) Cytokine Profile (IL-2, IL-6, IL-17, IL-22, and TNF-α) in Vitiligo-New Insight into Pathogenesis of Disease. Journal of Cosmetic Dermatology, 18, 337-341. https://doi.org/10.1111/jocd.12517
|
[38]
|
Bernardini, N., Skroza, N., Tolino, E., et al. (2020) IL-17 and Its Role in Inflammatory, Autoimmune, and Oncological Skin Diseases: State of Art. International Journal of Dermatology, 59, 406-411. https://doi.org/10.1111/ijd.14695
|
[39]
|
Kotobuki, Y., Tanemura, A., Yang, L., et al. (2012) Dysregulation of Melanocyte Function by Th17-Related Cytokines: Significance of Th17 Cell Infiltration in Autoimmune Vitiligo Vulgaris. Pigment Cell & Melanoma Research, 25, 219-230. https://doi.org/10.1111/j.1755-148X.2011.00945.x
|
[40]
|
Wang, W., et al. (2019) Astilbin Reduces ROS Accumulation and VEGF Expression through Nrf2 in Psoriasis-Like Skin Disease. Biological Research, 52, Article No. 49. https://doi.org/10.1186/s40659-019-0255-2
|
[41]
|
Speeckaert, R., Mylle, S. and Van Geel, N. (2019) IL-17A Is Not a Treatment Target in Progressive Vitiligo. Pigment Cell & Melanoma Research, 32, 842-847. https://doi.org/10.1111/pcmr.12789
|
[42]
|
Belpaire, A., Van Geel, N. and Speeckaert, R. (2022) From IL-17 to IFN-γ in Inflammatory Skin Disorders: Is Transdifferentiation a Potential Treatment Target? Frontiers in Immunology, 13, Article ID: 932265. https://doi.org/10.3389/fimmu.2022.932265
|